Atlas Trials

Castration Levels of Testosterone

19 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch Castration Levels of Testosterone

RecordFirmDate
Apalutamide With or Without Stereotactic Body Radiation in Treating Castration-Resistant Prostate Cancer (NCT03503344)University of California, San Francisco2019-12-17
sEphB4-HSA in Treating Patients With Metastatic Castration-Resistant Prostate Cancer (NCT04033432)Northwestern University2019-09-20
Enzalutamide With Venetoclax in Treating Patients With Metastatic Castration Resistant Prostate Cancer (NCT03751436)Roswell Park Cancer Institute2019-08-02
177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate Cancer (NCT03805594)University of California, San Francisco2019-05-10
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer (NCT03678025)SWOG Cancer Research Network2018-09-24
Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency (NCT03442556)University of Washington2018-08-24
Pembro and HER2Bi-Armed Activated T Cells in Treating Patients With Metastatic Castration Resistant Prostate Cancer (NCT03406858)Barbara Ann Karmanos Cancer Institute2018-06-07
Durvalumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer (NCT02966587)University of Washington2018-05-15
ESK981 in Treating Patients With Metastatic Castrate-Resistant Prostate Cancer (NCT03456804)Barbara Ann Karmanos Cancer Institute2018-03-08
Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer (NCT02703623)M.D. Anderson Cancer Center2016-05-18
Docetaxel and Carboplatin in Treating Patients With Metastatic, Castration Resistant Prostate Cancer Containing Inactivated Genes in the BRCA 1/2 Pathway (NCT02598895)University of Washington2016-01-26
Niclosamide and Enzalutamide in Treating Patients With Castration-Resistant, Metastatic Prostate Cancer (NCT02532114)University of Washington2015-12-31
Selinexor in Treating Patients With Abiraterone Acetate and/or Enzalutamide Refractory Metastatic Castration-Resistant Prostate Cancer (NCT02215161)University of California, San Francisco2014-09-02
CYT107 After Vaccine Treatment (Provenge®) in Patients With Metastatic Castration-Resistant Prostate Cancer (NCT01881867)Fred Hutchinson Cancer Center2013-09-10
Molecular Features and Pathways in Predicting Drug Resistance in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Enzalutamide (NCT02228265)OHSU Knight Cancer Institute2013-03-12

Track Castration Levels of Testosterone automatically

Every clearance here is in the API, with alerts when new ones post.